{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:16:39Z","timestamp":1791530199362,"version":"4.3.4"},"reference-count":47,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science KAKENHI","award":["JP17H06956"],"award-info":[{"award-number":["JP17H06956"]}]},{"name":"Japan Society for the Promotion of Science KAKENHI","award":["JP20K07593"],"award-info":[{"award-number":["JP20K07593"]}]},{"name":"Fukuoka Foundation for Sound Health Cancer Research Fund","award":["JP17H06956"],"award-info":[{"award-number":["JP17H06956"]}]},{"name":"Fukuoka Foundation for Sound Health Cancer Research Fund","award":["JP20K07593"],"award-info":[{"award-number":["JP20K07593"]}]},{"name":"OHARA Pharmaceutical Co","award":["JP17H06956"],"award-info":[{"award-number":["JP17H06956"]}]},{"name":"OHARA Pharmaceutical Co","award":["JP20K07593"],"award-info":[{"award-number":["JP20K07593"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The recent evolution of molecular targeted therapy has improved clinical outcomes in several human malignancies. The translocation of anaplastic lymphoma kinase (ALK) was originally identified in anaplastic large-cell lymphoma (ALCL) and subsequently in non-small cell lung carcinoma (NSCLC). Since ALK fusion gene products act as a driver of carcinogenesis in both ALCL and NSCLC, several ALK tyrosine kinase inhibitors (TKIs) have been developed. Crizotinib and alectinib are first- and second-generation ALK TKIs, respectively, approved for the treatment of ALK-positive ALCL (ALK+ ALCL) and ALK+ NSCLC. Although most ALK+ NSCLC patients respond to crizotinib and alectinib, they generally relapse after several years of treatment. We previously found that DNA-demethylating agents enhanced the efficacy of ABL TKIs in chronic myeloid leukemia cells. Moreover, aberrant DNA methylation has also been observed in ALCL cells. Thus, to improve the clinical outcomes of ALK+ ALCL therapy, we investigated the synergistic efficacy of the combination of alectinib and the DNA-demethylating agent azacytidine, decitabine, or OR-2100 (an orally bioavailable decitabine derivative). As expected, the combination of alectinib and DNA-demethylating agents synergistically suppressed ALK+ ALCL cell proliferation, concomitant with DNA hypomethylation and a reduction in STAT3 (a downstream target of ALK fusion proteins) phosphorylation. The combination of alectinib and OR-2100 markedly altered gene expression in ALCL cells, including that of genes implicated in apoptotic signaling, which possibly contributed to the synergistic anti-ALCL effects of this drug combination. Therefore, alectinib and OR-2100 combination therapy has the potential to improve the outcomes of patients with ALK+ ALCL.<\/jats:p>","DOI":"10.3390\/cancers15205089","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T12:59:48Z","timestamp":1697893188000},"page":"5089","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation"],"prefix":"10.3390","volume":"15","author":[{"given":"Kazunori","family":"Kawasoe","sequence":"first","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"},{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Yoshida-Sakai","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"},{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"},{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kurahashi","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"},{"name":"OHARA Pharmaceutical Co., Ltd., Koka 520-3403, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kidoguchi","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"},{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3699","authenticated-orcid":false,"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"},{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7346-4864","authenticated-orcid":false,"given":"Kazuharu","family":"Kamachi","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"},{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fukuda-Kurahashi","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"},{"name":"OHARA Pharmaceutical Co., Ltd., Koka 520-3403, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan"},{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhang, X.R., Chien, P.N., Nam, S.Y., and Heo, C.Y. (2022). Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment. Cancers, 14.","DOI":"10.3390\/cancers14071650"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bjh.13958","article-title":"Anaplastic large cell lymphoma in paediatric and young adult patients","volume":"173","author":"Turner","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ducray, S.P., Natarajan, K., Garland, G.D., Turner, S.D., and Egger, G. (2019). The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis. Cancers, 11.","DOI":"10.3390\/cancers11081074"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1158\/1078-0432.CCR-12-0550","article-title":"Identifying and targeting ROS1 gene fusions in non-small cell lung cancer","volume":"18","author":"Davies","year":"2012","journal-title":"Clin. Cancer Res.Off. J. Am. Assoc. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children\u2019s Oncology Group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ajh.25043","article-title":"Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study","volume":"93","author":"Orlov","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic Therapies for Cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: A versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1182\/blood-2005-08-007377","article-title":"STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes","volume":"108","author":"Zhang","year":"2006","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.biochi.2012.05.029","article-title":"Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2\u2032-deoxycytidine in anaplastic large cell lymphoma","volume":"94","author":"Hassler","year":"2012","journal-title":"Biochimie"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e202000794","DOI":"10.26508\/lsa.202000794","article-title":"Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis","volume":"4","author":"Redl","year":"2021","journal-title":"Life Sci. Alliance"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.celrep.2016.09.018","article-title":"Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling","volume":"17","author":"Hassler","year":"2016","journal-title":"Cell Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/S0002-9440(10)61178-9","article-title":"Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors","volume":"160","author":"Rassidakis","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jcp.2004.022335","article-title":"High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma","volume":"58","author":"Rust","year":"2005","journal-title":"J. Clin. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1182\/blood-2010-09-301994","article-title":"MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression","volume":"117","author":"Desjobert","year":"2011","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/sj.leu.2404323","article-title":"Restoration of shp1 expression by 5-AZA-2\u2032-deoxycytidine is associated with downregulation of JAK3\/STAT3 signaling in ALK-positive anaplastic large cell lymphoma","volume":"20","author":"Han","year":"2006","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1172\/JCI78488","article-title":"Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth","volume":"125","author":"Valentin","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13148-019-0709-y","article-title":"Novel prodrugs of decitabine with greater metabolic stability and less toxicity","volume":"11","author":"Hattori","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.2019003084","article-title":"Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100","volume":"136","author":"Watanabe","year":"2020","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.canlet.2021.11.032","article-title":"Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia","volume":"526","author":"Kamachi","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1535-7163.MCT-20-1125","article-title":"Silylation of deoxynucleotide analog yields an orally available drug with anti-leukemia effects","volume":"20","author":"Ureshino","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: Visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1158\/2767-9764.CRC-22-0259","article-title":"Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia","volume":"3","author":"Kamachi","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lisanti, S., Omar, W.A., Tomaszewski, B., De Prins, S., Jacobs, G., Koppen, G., Mathers, J.C., and Langie, S.A. (2013). Comparison of methods for quantification of global DNA methylation in human cells and tissues. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079044"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"815654","DOI":"10.3389\/fonc.2022.815654","article-title":"Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_36","first-page":"53","article-title":"Secreted frizzled related proteins: Implications in cancers","volume":"1845","author":"Surana","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_37","first-page":"3481","article-title":"Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta-analysis","volume":"18","author":"Yu","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3324\/haematol.2010.027086","article-title":"beta-catenin is constitutively active and increases STAT3 expression\/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","volume":"96","author":"Anand","year":"2011","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/j.clml.2019.03.030","article-title":"p53 and beta-Catenin Expression Predict Poorer Prognosis in Patients With Anaplastic Large-Cell Lymphoma","volume":"19","author":"Richardson","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","article-title":"An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: A multicentre, open-label, dose-escalation, phase 1 study","volume":"6","author":"Savona","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_41","first-page":"2760","article-title":"Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia","volume":"30","author":"Li","year":"1970","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Arosio, G., Sharma, G.G., Villa, M., Mauri, M., Crespiatico, I., Fontana, D., Manfroni, C., Mastini, C., Zappa, M., and Magistroni, V. (2021). Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13174422"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30149","DOI":"10.18632\/oncotarget.4999","article-title":"Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma","volume":"6","author":"Mitou","year":"2015","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"16211","DOI":"10.1073\/pnas.1312938110","article-title":"GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding","volume":"110","author":"Gomes","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/npp.2017.79","article-title":"The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning","volume":"42","author":"Bobeck","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1038\/s41467-021-26135-9","article-title":"The GPR171 pathway suppresses T cell activation and limits antitumor immunity","volume":"12","author":"Fujiwara","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/20\/5089\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:09:32Z","timestamp":1760130572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/20\/5089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":47,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15205089"],"URL":"https:\/\/doi.org\/10.3390\/cancers15205089","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,21]]}}}